Muscle loss and GLP-1R agonists use
US$ 20.04
glp-1 moa Mechanism of action of agonists – My Endo Consult Glucagon-like peptide 1 (GLP-1) -
Description
Diabetes (2005) 54(Suppl 2):S117
According to FDA prescribing information, these include: Nausea (occurring in 1544% of patients depending on the specific agent and dose) Vomiting (524% of patients) Diarrhea (821% of patients) Constipation (1024% of patients) Abdominal pain or discomfort (514% of patients) These symptoms typically emerge during dose initiation or escalation and often diminish over several weeks as the body adapts
Only about half (52%) of GLP-1 users we talked to liked the protein supplements currently on the market
References Aarsland D, Pahlhagen S, Ballard CG, Ehrt U, Svenningsson P
